Drug delivery systems for oestrogenic hormones and antagonists: The need for selective targeting in estradiol-dependent cancers

Journal of Steroid Biochemistry and Molecular Biology

Volumn 92, Issue 1-2, 2004, Pages 1-18

  Ameller, Thibault ^a   Legrand, Philippe ^a   Marsaud, Véronique ^a   Renoir, Jack Michel ^a  

^a UNIV PARIS SUD   (France)

Author keywords

Anti oestrogen; Breast cancer; Contraception; Drug delivery; Hormone replacement therapy; Oestrogen

Indexed keywords

11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL] ESTRADIOL; 11 [4 [[5 [(4,4,5,5,5 PENTAFLUOROPENTYL)SULFONYL]PENTYL]OXY]PHENYL]ESTRADIOL; 4 [4 METHYL 2 [4 [2 (1 PIPERIDINYL)ETHOXY]PHENYL] 7 PIVALOYLOXY 2H 1 BENZOPYRAN 3 YLPHENYL] PIVALATE; 4 HYDROXYTAMOXIFEN; ACOLBIFENE; ANTIESTROGEN; APRI; AVIANE; COMBINED INJECTABLE CONTRACEPTIVE; COPPER INTRAUTERINE DEVICE; CYCLESSA; DESOGESTREL PLUS ETHINYLESTRADIOL; DROLOXIFENE; DROSPIRENONE PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTRADIOL CYPIONATE PLUS MEDROXYPROGESTERONE ACETATE; ESTROGEN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ETHINYLESTRADIOL PLUS ETONOGESTREL; ETHINYLESTRADIOL PLUS ETYNODIOL DIACETATE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; ETHINYLESTRADIOL PLUS NORELGESTROMIN; ETHINYLESTRADIOL PLUS NORETHISTERONE; ETHINYLESTRADIOL PLUS NORETHISTERONE ACETATE; ETHINYLESTRADIOL PLUS NORGESTIMATE; ETHINYLESTRADIOL PLUS NORGESTREL; ETONOGESTREL; FIBROPLANT; FULVESTRANT; HEAT SHOCK PROTEIN 90; JENEST 28; LEVONORGESTREL; LEVORA; LOW OGESTREL; MEDROXYPROGESTERONE ACETATE; MESTRANOL PLUS NORETHISTERONE; NECON; NORETHIN; OGESTREL; ORAL CONTRACEPTIVE AGENT; OVCON 50; RALOXIFENE; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; TOREMIFENE; TRIVORA; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOVIA;

AMENORRHEA; BIODEGRADATION; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG TARGETING; ESTROGEN THERAPY; HORMONAL CONTRACEPTION; HUMAN; INTERMETHOD COMPARISON; INTRAUTERINE CONTRACEPTIVE DEVICE; MENOPAUSE; MOLECULAR MECHANICS; NONHUMAN; OSTEOPOROSIS; REVIEW; SKIN PENETRATION; TRANSDERMAL PATCH; VAGINA BLEEDING; VASOMOTOR DISORDER; XENOGRAFT;

ANTINEOPLASTIC AGENTS, HORMONAL; CONTRACEPTION; DRUG DELIVERY SYSTEMS; ESTROGEN ANTAGONISTS; ESTROGENS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS;

EID: 8444221337     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2004.05.006     Document Type: Review

References (170)

1. A. Weisz, and F. Bresciani Oestrogen regulation of proto-oncogenes coding for nuclear proteins Crit. Rev. Oncog. 4 1993 361 388
2. D. Toft, and J. Gorski A receptor molecule for oestrogens: isolation from the rat uterus and preliminary characterization Proc. Natl. Acad. Sci. U.S.A. 55 1966 1574 1581
3. E.V. Jensen, and H.I. Jacobson Basic guides to the mechanism of oestrogen action Recent Prog. Horm. Res. 18 1962 337 414
4. G.G. Kuiper, E. Enmark, M. Pelto-Huikko, S. Nilsson, and J.A. Gustafsson Cloning of a novel receptor expressed in rat prostate and ovary Proc. Natl. Acad. Sci. U.S.A. 93 1996 5925 5930
5. S. Mosselman, J. Polman, and R. Dijkema ER beta: identification and characterization of a novel human oestrogen receptor FEBS Lett. 392 1996 49 53
6. B.S. Katzenellenbogen, and K.S. Korach A new actor in the oestrogen receptor drama-enter ER-beta Endocrinology 138 1997 861 862
7. S. Kousteni, T. Bellido, L.I. Plotkin, C.A. O'Brien, D.L. Bodenner, L. Han, K. Han, G.B. DiGregorio, J.A. Katzenellenbogen, B.S. Katzenellenbogen, P.K. Roberson, R.S. Weinstein, R.L. Jilka, and S.C. Manolagas Nongenotropic, sex-nonspecific signaling through the oestrogen or androgen receptors: dissociation from transcriptional activity Cell 104 2001 719 730
8. M. Marino, F. Acconcia, F. Bresciani, A. Weisz, and A. Trentalance Distinct nongenomic signal transduction pathways controlled by 17beta-estradiol regulate DNA synthesis and cyclin D1 gene transcription in HepG2 cells Mol. Biol. Cell 13 2002 3720 3729
9. M.J. Kelly, and E.R. Levin Rapid actions of plasma membrane oestrogen receptors Trends Endocrinol. Metab. 12 2001 152 156
10. J.I. MacGregor, and V.C. Jordan Basic guide to the mechanisms of anti-oestrogen action Pharmacol. Rev. 50 1998 151 196
11. V.C. Jordan Anti-oestrogens and selective estrogen receptor modulators as multifunctionnal medicines. 2. Clinical considerations and new agents J. Med. Chem. 46 2003 1081 1111
12. P. Webb, G.N. Lopez, R.M. Uht, and P.J. Kushner Tamoxifen activation of the oestrogen receptor/AP-1 pathway: potential origin for the cell-specific oestrogen-like effects of anti-oestrogens Mol. Endocrinol. 9 1995 443 456
13. K. Paech, P. Webb, G.G. Kuiper, S. Nilsson, J. Gustafsson, P.J. Kushner, and T.S. Scanlan Differential ligand activation of oestrogen receptors ERα and ERβ at AP1 sites Science 277 1997 1508 1510
14. P.J. Kushner, D.A. Agard, G.L. Greene, T.S. Scanlan, A.K. Shiau, R.M. Uht, and P. Webb Oestrogen receptor pathways to AP-1 J. Steroid Biochem. Mol. Biol. 74 2000 311 317
15. V.C. Jordan Targeted anti-oestrogens to prevent breast cancer Trends Endocrinol. Metab. 10 1999 312 317
16. M. Beato, P. Herrlich, and G. Schutz Steroid hormone receptors: many actors in search of a plot Cell 83 1995 851 857
17. M.J. Tsai, and B.W. O'Malley Molecular mechanisms of action of steroid/thyroid receptor superfamily members Annu. Rev. Biochem. 63 1994 451 486
18. S. Nilsson, S. Makela, E. Treuter, M. Tujague, J. Thomsen, G. Andersson, E. Enmark, K. Pettersson, M. Warner, and J.A. Gustafsson Mechanisms of oestrogen action Physiol. Rev. 81 2001 1535 1565
19. W.B. Pratt, and D.O. Toft Steroid receptor interactions with heat shock protein and immunophilin chaperones Endocr. Rev. 18 1997 306 360
20. M.M. Gottardis, S.P. Robinson, P.G. Satyaswaroop, and V.C. Jordan Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse Cancer Res. 48 1988 812 815
21. W.B. Pratt The role of the hsp90-based chaperone system in signal transduction by nuclear receptors and receptors signaling via MAP kinase Annu. Rev. Pharmacol. Toxicol. 37 1997 297 326
22. I. Joab, C. Radanyi, M. Renoir, T. Buchou, M.G. Catelli, N. Binart, J. Mester, and E.E. Baulieu Common non-hormone binding component in non-transformed chick oviduct receptors of four steroid hormones Nature 308 1984 850 853
23. J.L. Johnson, and D.O. Toft A novel chaperone complex for steroid receptors involving heat shock proteins, immunophilins, and p23 J. Biol. Chem. 269 1994 24989 24993
24. J.P. Grenert, W.P. Sullivan, P. Fadden, T.A. Haystead, J. Clark, E. Mimnaugh, H. Krutzsch, H.J. Ochel, T.W. Schulte, E. Sausville, L.M. Neckers, and D.O. Toft The amino-terminal domain of heat shock protein 90 (hsp90) that binds geldanamycin is an ATP/ADP switch domain that regulates hsp90 conformation J. Biol. Chem. 272 1997 23843 23850
25. B.C. Freeman, S.J. Felts, D.O. Toft, and K.R. Yamamoto The p23 molecular chaperones act at a late step in intracellular receptor action to differentially affect ligand efficacies Genes Dev. 14 2000 422 434
26. D.L. Stenoien, K. Patel, M.G. Mancini, M. Dutertre, C.L. Smith, B.W. O'Malley, and M.A. Mancini FRAP reveals that mobility of oestrogen receptor-alpha is ligand- and proteasome-dependent Nat. Cell Biol. 3 2001 15 23
27. C.M. Klinge Oestrogen receptor interaction with co-activators and co-repressors Steroids 65 2000 227 251
28. D. Robyr, A.P. Wolffe, and W. Wahli Nuclear hormone receptor coregulators in action: diversity for shared tasks Mol. Endocrinol. 14 2000 329 347
29. T.E. Spencer, G. Jenster, M.M. Burcin, C.D. Allis, J. Zhou, C.A. Mizzen, N.J. McKenna, S.A. Onate, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley Steroid receptor coactivator-1 is a histone acetyltransferase Nature 389 1997 194 198
30. R. Metivier, G. Penot, M.R. Hubner, G. Reid, H. Brand, M. Kos, and F. Gannon Oestrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter Cell 115 2003 751 763
31. M.M. Montano, K. Ekena, R. Delage-Mourroux, W. Chang, P. Martini, and B.S. Katzenellenbogen An oestrogen receptor-selective coregulator that potentiates the effectiveness of anti-oestrogens and represses the activity of oestrogens Proc. Natl. Acad. Sci. U.S.A. 1999 96
32. H. Chen, R.J. Lin, R.L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M.L. Privalsky, Y. Nakatani, and R.M. Evans Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300 Cell 90 1997 569 580
33. N.L. Weigel Steroid hormone receptors and their regulation by phosphorylation Biochem. J. 319 1996 657 667
34. G. Bunone, P.A. Briand, R.J. Miksicek, and D. Picard Activation of the unliganded oestrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation Embo J. 15 1996 2174 2183
35. P.B. Joel, J. Smith, T.W. Sturgill, T.L. Fisher, J. Blenis, and D.A. Lannigan pp90rsk1 regulates oestrogen receptor-mediated transcription through phosphorylation of Ser-167 Mol. Cell Biol. 18 1998 1978 1984
36. E.J. Filardo, J.A. Quinn, K.I. Bland, and A.R. Frackelton Jr. Oestrogen-induced activation of Erk-1 and Erk-2 requires the G protein-coupled receptor homolog, GPR30, and occurs via trans-activation of the epidermal growth factor receptor through release of HB-EGF Mol. Endocrinol. 2000 14
37. M. Razandi, G. Alton, A. Pedram, S. Ghonshani, P. Webb, and E.R. Levin Identification of a structural determinant necessary for the localization and function of oestrogen receptor alpha at the plasma membrane Mol. Cell Biol. 23 2003 1633 1646
38. Z. Nawaz, D.M. Lonard, A.P. Dennis, C.L. Smith, and B.W. O'Malley Proteasome-dependent degradation of the human oestrogen receptor Proc. Natl. Acad. Sci. U.S.A. 96 1999 1858 1862
39. E.T. Alarid, N. Bakopoulos, and N. Solodin Proteasome-mediated proteolysis of oestrogen receptor: a novel component in autologous down-regulation Mol. Endocrinol. 13 1999 1522 1534
40. D.M. Lonard, Z. Nawaz, C.L. Smith, and B.W. O'Malley The 26S proteasome is required for oestrogen receptor-alpha and coactivator turnover and for efficient oestrogen receptor-alpha transactivation Mol. Cell 5 2000 939 948
41. A.L. Wijayaratne, and D.P. McDonnell The human oestrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective oestrogen receptor modulators J. Biol. Chem. 276 2001 35684 35692
42. A. El Khissiin, and G. Leclercq Implication of proteasome in oestrogen receptor degradation FEBS Lett. 448 1999 160 166
43. V. Marsaud, A. Gougelet, S. Maillard, and J.M. Renoir Various phosphorylation pathways, depending on agonist and antagonist binding to endogenous oestrogen receptor alpha (ERα), differentially affect ERα extractability, proteasome-mediated stability, and transcriptional activity in human breast cancer cells Mol. Endocrinol. 17 2003 2013 2027
44. B. Segnitz, and U. Gehring The function of steroid hormone receptors is inhibited by the hsp90-specific compound geldanamycin J. Biol. Chem. 1997 272
45. R. Bagatell, O. Khan, G. Paine-Murrieta, C.W. Taylor, S. Akinaga, and L. Whitesell Destabilization of steroid receptors by heat shock protein 90-binding drugs: a ligand-independent approach to hormonal therapy of breast cancer Clin. Cancer Res. 7 2001 2076 2084
46. L. Neckers Hsp90 inhibitors as novel cancer chemotherapeutic agents Trends Mol. Med. 8 2002 55 61
47. O. Lidegaard, and I. Milsom Oral contraceptives and thrombotic diseases: impact of new epidemiological studies Contraception 53 1996 135 139
48. Ortho Pharmaceutical Corp., Annual Birth Control Study, Raritan, NJ, 1997.
49. I.F. Godsland, and D. Crook Update on the metabolic effects of steroidal contraceptives and their relationship to cardiovascular disease risk Am. J. Obstet. Gynecol. 170 1994 1528 1536
50. L. Speroff, J. Rowan, J. Symons, H. Genant, and W. Wilborn The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial JAMA 276 1996 1397 1403
51. M. Wallach D.A. Grimes Modern Oral Contraception: Updates From the Contraception Report 2000 Emron Totowa, NJ 70 76
52. H.A. van Vliet, D.A. Grimes, F.M. Helmerhorst, and K.F. Schulz Biphasic versus triphasic oral contraceptives for contraception Contraception 65 2002 321 324
53. A. Nelson, R.A. Hatcher, M. Zieman, A. Watt, P.D. Darney, M.D. Creinin, A Pocket Guide to Managing Contraception, 4th ed. Tiger, G.A., 2000.
54. A.M. Kaunitz, R.J. Garceau, and M.A. Cromie Comparative safety, efficacy, and cycle control of Lunelle monthly contraceptive injection (medroxyprogesterone acetate and estradiol cypionate injectable suspension) and Ortho-Novum 7/7/7 oral contraceptive (norethindrone/ethinyl estradiol triphasic). Lunelle Study Group Contraception 60 1999 179 187
55. X.F. Zhou, Q.X. Shao, X.J. Han, L.J. Weng, and G.W. Sang Pharmacokinetics of medroxyprogesterone acetate after single and multiple injection of cyclofem in Chinese women Contraception 57 1998 405 411
56. R.J. Scheuplein, I.H. Blank, G.J. Brauner, and D.J. MacFarlane Percutaneous absorption of steroids J. Invest. Dermatol. 52 1969 63 70
57. C.H. Vickers Reservoir effect of human skin: pharmacological speculation J. Wepierre Percutaneous Absorption of Steroids 1980 Academic Press London 19 29
58. D.R. Friend Transdermal delivery of contraceptives Crit. Rev. Ther. Drug Carrier Syst. 7 1990 149 186
59. G.H. Smallwood, M.L. Meador, J.P. Lenihan, G.A. Shangold, A.C. Fisher, and G.W. Creasy Efficacy and safety of a transdermal contraceptive system Obstet. Gynecol. 98 2001 799 805
60. M.C. Audet, M. Moreau, W.D. Koltun, A.S. Waldbaum, G. Shangold, A.C. Fisher, and G.W. Creasy Evaluation of contraceptive efficacy and cycle control of a transdermal contraceptive patch vs. an oral contraceptive: a randomized controlled trial JAMA 285 2001 2347 2354
61. Pharmacia and Upjohn Inc., International Survey of Birth Control Methods and What Women Want, 2001.
62. T.M. Mulders, and T.O. Dieben Use of the novel combined contraceptive vaginal ring NuvaRing for ovulation inhibition Fertil. Steril. 75 2001 865 870
63. F. Roumen Contraceptive efficacy and tolerability with a novel combined contraceptive vaginal ring, NuvaRing Eur. J. Contracept Reprod. Health Care 7 2002 19 24
64. J. Studd, B. Pornel, I. Marton, J. Bringer, C. Varin, Y. Tsouderos, and C. Christiansen Efficacy and acceptability of intranasal 17 beta-oestradiol for menopausal symptoms: randomised dose-response study. Aerodiol Study Group Lancet 353 1999 1574 1578
65. L.A. Mattsson, C. Christiansen, J.C. Colau, S. Palacios, P. Kenemans, C. Bergeron, O. Chevallier, T. Von Holst, and K. Gangar Clinical equivalence of intranasal and oral 17beta-estradiol for postmenopausal symptoms Am. J. Obstet. Gynecol. 182 2000 545 552
66. N. Panay, K. Toth, C. Pelissier, and J. Studd Dose-ranging studies of a novel intranasal oestrogen replacement therapy Maturitas 38 2001 15 22
67. R.N. Smith, and J.W. Studd Recent advances in hormone replacement therapy Br. J. Hosp. Med. 49 1993 799 808
68. J.G. Greene Constructing a standard climacteric scale Maturitas 29 1998 25 31
69. B.M. Feldman, A. Voda, and E. Gronseth The prevalence of hot flash and associated variables among perimenopausal women Res. Nurs. Health 8 1985 261 268
70. L. Cardozo, G. Bachmann, D. McClish, D. Fonda, and L. Birgerson Meta-analysis of oestrogen therapy in the management of urogenital atrophy in postmenopausal women: second report of the Hormones and Urogenital Therapy Committee Obstet. Gynecol. 92 1998 722 727
71. G.A. Bachmann Vasomotor flushes in menopausal women Am. J. Obstet. Gynecol. 180 1999 312 316
72. M.A. Limouzin-Lamothe, N. Mairon, C.R. Joyce, and M. Le Gal Quality of life after the menopause: influence of hormonal replacement therapy Am. J. Obstet. Gynecol. 170 1994 618 624
73. P. Bech, N. Munk-Jensen, E.B. Obel, L.G. Ulrich, P. Eiken, and S.P. Nielsen Combined versus sequential hormonal replacement therapy: a double-blind, placebo-controlled study on quality of life-related outcome measures Psychother. Psychosom. 67 1998 259 265
74. W.M. van Baal, T. Kooistra, and C.D. Stehouwer Cardiovascular disease risk and hormone replacement therapy (HRT): a review based on randomised, controlled studies in postmenopausal women Curr. Med. Chem. 7 2000 499 517
75. Effects of oestrogen or oestrogen/progestin regimens on heart disease risk factors in postmenopausal women, The Postmenopausal Oestrogen/Progestin Interventions (PEPI) Trial, The Writing Group for the PEPI Trial, JAMA 273 (1995) 199-208.
76. C.J. Boushey, S.A. Beresford, G.S. Omenn, and A.G. Motulsky A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes JAMA 1995 274
77. H. Refsum, P.M. Ueland, O. Nygard, and S.E. Vollset Homocysteine and cardiovascular disease Annu. Rev. Med. 49 1998 31 62
78. S. Hulley, D. Grady, T. Bush, C. Furberg, D. Herrington, B. Riggs, and E. Vittinghoff Randomized trial of oestrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Oestrogen/progestin Replacement Study (HERS) Research Group JAMA 280 1998 605 613
79. V. Beral, E. Banks, and G. Reeves Evidence from randomised trials on the long-term effects of hormone replacement therapy Lancet 360 2002 942 944
80. J.E. Rossouw, G.L. Anderson, R.L. Prentice, A.Z. LaCroix, C. Kooperberg, M.L. Stefanick, R.D. Jackson, S.A. Beresford, B.V. Howard, K.C. Johnson, J.M. Kotchen, and J. Ockene Risks and benefits of oestrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial JAMA 288 2002 321 333
81. F. Albright, P.H. Smith, and A.M. Richardson Hormone replacement therapy and bone metabolism JAMA 116 1941 2465 2468
82. P.D. Delmas, B. Pornel, D. Felsenberg, P. Garnero, P. Hardy, C. Pilate, and M.P. Dain A dose-ranging trial of a matrix transdermal 17beta-estradiol for the prevention of bone loss in early postmenopausal women. International Study Group Bone 24 1999 517 523
83. M. Gambacciani, M. Ciaponi, B. Cappagli, and A.R. Genazzani Effects of low-dose continuous combined conjugated oestrogens and medroxyprogesterone acetate on menopausal symptoms, body weight, bone density, and metabolism in postmenopausal women Am. J. Obstet. Gynecol. 185 2001 1180 1185
84. D.J. Torgerson, and S.E. Bell-Syer Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials JAMA 285 2001 2891 2897
85. C. Christiansen, and B.J. Riis 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women J. Clin. Endocrinol. Metab. 71 1990 836 841
86. R.R. Recker, K.M. Davies, R.M. Dowd, and R.P. Heaney The effect of low-dose continuous oestrogen and progesterone therapy with calcium and Vitamin D on bone in elderly women. A randomized, controlled trial Ann. Intern. Med. 130 1999 897 904
87. M. Komulainen, H. Kroger, M.T. Tuppurainen, A.M. Heikkinen, R. Honkanen, and S. Saarikoski Identification of early postmenopausal women with no bone response to HRT: results of a five-year clinical trial Osteoporos Int. 11 2000 211 218
88. R.K. Ross, A. Paganini-Hill, V.R. Gerkins, T.M. Mack, R. Pfeffer, M. Arthur, and B.E. Henderson A case-control study of menopausal oestrogen therapy and breast cancer JAMA 243 1980 1635 1639
89. J.L. Stanford, N.S. Weiss, L.F. Voigt, J.R. Daling, L.A. Habel, and M.A. Rossing Combined oestrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women JAMA 274 1995 137 142
90. I. Persson, E. Weiderpass, L. Bergkvist, R. Bergstrom, and C. Schairer Risks of breast and endometrial cancer after oestrogen and oestrogen-progestin replacement Cancer Causes Control 10 1999 253 260
91. C. Magnusson, J.A. Baron, N. Correia, R. Bergstrom, H.O. Adami, and I. Persson Breast-cancer risk following long-term oestrogen- and oestrogen-progestin-replacement therapy Int. J. Cancer 81 1999 339 344
92. C. Schairer, J. Lubin, R. Troisi, S. Sturgeon, L. Brinton, and R. Hoover Menopausal oestrogen and oestrogen-progestin replacement therapy and breast cancer risk JAMA 283 2000 485 491
93. C.L. Chen, N.S. Weiss, P. Newcomb, W. Barlow, and E. White Hormone replacement therapy in relation to breast cancer JAMA 287 2002 734 741
94. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer, Collaborative Group on Hormonal Factors in Breast Cancer, Lancet 350 (1997) 1047-1059.
95. A.R. Folsom, P.J. Mink, T.A. Sellers, C.P. Hong, W. Zheng, and J.D. Potter Hormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women Am. J. Public Health 85 1995 1128 1132
96. G.L. Anderson, M. Limacher, A.R. Assaf, T. Bassford, S.A. Beresford, H. Black, D. Bonds, R. Brunner, R. Brzyski, B. Caan, R. Chlebowski, D. Curb, M. Gass, J. Hays, G. Heiss, S. Hendrix, B.V. Howard, J. Hsia, A. Hubbell, R. Jackson, K.C. Johnson, H. Judd, J.M. Kotchen, L. Kuller, A.Z. LaCroix, D. Lane, R.D. Langer, N. Lasser, C.E. Lewis, J. Manson, K. Margolis, J. Ockene, M.J. O'Sullivan, L. Phillips, R.L. Prentice, C. Ritenbaugh, J. Robbins, J.E. Rossouw, G. Sarto, M.L. Stefanick, L. Van Horn, J. Wactawski-Wende, R. Wallace, and S. Wassertheil-Smoller Effects of conjugated equine oestrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial JAMA 291 2004 1701 1712
97. L. Holmberg, and H. Anderson HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomised comparison: trial stopped Lancet 363 2004 453 455
98. A. Jarvinen, S. Nykanen, and L. Paasiniemi Absorption and bioavailability of oestradiol from a gel, a patch and a tablet Maturitas 32 1999 103 113
99. E. Baracat, M. Haidar, A. Castelo, S. Tufik, G.R. de Lima, J.G. Vieira, U. Peloso, and J. Casoy Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women Maturitas 23 1996 285 291
100. E. Baracat, S. Tufik, and A. Castelo Comparative bioavailaibility study of a matrix versus a reservoir transdermal estradiol patch in healthy postmenopausal women Curr. Ther. Res. 56 1995 358 368
101. M.J. Tikkanen Sex hormones J. Sheperd Lipoproteins in Health and Disease 1999 Arnold London 967 984
102. R.G. Smolders, M.J. van der Mooren, T. Teerlink, J.M. Merkus, M.V. Kroeks, H.R. Franke, C.D. Stehouwer, and P. Kenemans A randomized placebo-controlled study of the effect of transdermal vs. oral estradiol with or without gestodene on homocysteine levels Fertil. Steril. 79 2003 261 267
103. H. Buckler, and F. Al-Azzawi The effect of a novel vaginal ring delivering oestradiol acetate on climacteric symptoms in postmenopausal women Br. J. Obstet. Gynaecol. 110 2003 753 759
104. G. Hall, M. Blomback, B.M. Landgren, and K. Bremme Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women Fertil. Steril. 78 2002 1172 1177
105. C. Jung-Hoffman, and H. Kuhl Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism Am. J. Obstet. Gynecol. 163 1990 2183 2197
106. R. Tepper, S. Goldberger, I. Cohen, J. Segal, S. Yarkoni, M. Fejgin, and Y. Beyth Oestrogen replacement in postmenopausal women: are we currently overdosing our patients? Gynecol. Obstet. Investig. 38 1994 113 116
107. V.C. Jordan Anti-oestrogens: clinical applications of pharmacology J. Soc. Gynecol. Investig. 7 2000 S47 S48
108. I.A. Jaiyesimi, A.U. Buzdar, D.A. Decker, and G.N. Hortobagyi Use of tamoxifen for breast cancer: twenty-eight years later J. Clin. Oncol. 13 1995 513 529
109. T.J. Powles Efficacy of tamoxifen as treatment of breast cancer Semin. Oncol. 24 1997 S48 S54
110. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women, Early Breast Cancer Trialists' Collaborative Group, Lancet 339 (1992) 71-85.
111. B. Fisher, J.P. Costantino, D.L. Wickerham, C.K. Redmond, M. Kavanah, W.M. Cronin, V. Vogel, A. Robidoux, N. Dimitrov, J. Atkins, M. Daly, S. Wieand, E. Tan-Chiu, L. Ford, and N. Wolmark Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study J. Natl. Cancer Inst. 90 1998 1371 1388
112. K. Holli, R. Valavaara, G. Blanco, V. Kataja, P. Hietanen, M. Flander, E. Pukkala, and H. Joensuu Safety and efficacy results of a randomized trial comparing adjuvant toremifene and tamoxifen in postmenopausal patients with node-positive breast cancer. Finnish Breast Cancer Group J. Clin. Oncol. 18 2000 3487 3494
113. L. Kangas, A.L. Nieminen, G. Blanco, M. Gronroos, S. Kallio, A. Karjalainen, M. Perila, M. Sodervall, and R. Toivola A new triphenylethylene compound, Fc-1157a. II. Antitumor effects Cancer Chemother. Pharmacol. 17 1986 109 113
114. S.P. Robinson, and V.C. Jordan Anti-oestrogenic action of toremifene on hormone-dependent, -independent, and heterogeneous breast tumor growth in the athymic mouse Cancer Res. 49 1989 1758 1762
115. E. Tomas, A. Kauppila, G. Blanco, M. Apaja-Sarkkinen, and T. Laatikainen Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients Gynecol. Oncol. 59 1995 261 266
116. P.D. Delmas, N.H. Bjarnason, B.H. Mitlak, A.C. Ravoux, A.S. Shah, W.J. Huster, M. Draper, and C. Christiansen Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women N. Engl. J. Med. 337 1997 1641 1647
117. S.R. Cummings, S. Eckert, K.A. Krueger, D. Grady, T.J. Powles, J.A. Cauley, L. Norton, T. Nickelsen, N.H. Bjarnason, M. Morrow, M.E. Lippman, D. Black, J.E. Glusman, A. Costa, and V.C. Jordan The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation JAMA 281 1999 2189 2197
118. M. Hasmann, B. Rattel, and R. Loser Preclinical data for droloxifene Cancer Lett. 84 1994 101 116
119. I.N. White, F. de Matteis, A. Davies, L.L. Smith, C. Crofton-Sleigh, S. Venitt, A. Hewer, and D.H. Phillips Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells Carcinogenesis 13 1992 2197 2203
120. U. Eppenberger, K. Wosikowski, and W. Kung Pharmacologic and biologic properties of droloxifene, a new anti-oestrogen Am. J. Clin. Oncol. 14 1991 5 14
121. W. Rauschning, and K.I. Pritchard Droloxifene, a new anti-oestrogen: its role in metastatic breast cancer Breast Cancer Res. Treat. 31 1994 83 94
122. F. Labrie, C. Labrie, A. Belanger, J. Simard, S. Gauthier, V. Luu-The, Y. Merand, V. Giguere, B. Candas, S. Luo, C. Martel, S.M. Singh, M. Fournier, A. Coquet, V. Richard, R. Charbonneau, G. Charpenet, A. Tremblay, G. Tremblay, L. Cusan, and R. Veilleux EM-652 (SCH 57068), a third generation SERM acting as pure anti-oestrogen in the mammary gland and endometrium J. Steroid Biochem. Mol. Biol. 69 1999 51 84
123. A. Howell, D.J. DeFriend, J.F. Robertson, R.W. Blamey, L. Anderson, E. Anderson, F.A. Sutcliffe, and P. Walton Pharmacokinetics, pharmacological and anti-tumour effects of the specific anti-oestrogen ICI182780 in women with advanced breast cancer Br. J. Cancer 74 1996 300 308
124. C.K. Osborne, J. Pippen, S.E. Jones, L.M. Parker, M. Ellis, S. Come, S.Z. Gertler, J.T. May, G. Burton, I. Dimery, A. Webster, C. Morris, R. Elledge, and A. Buzdar Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial J. Clin. Oncol. 20 2002 3386 3395
125. A. Howell, and J. Robertson Response to a specific antioestrogen (ICI182780) in tamoxifen-resistant breast cancer Lancet 345 1995 989 990
126. L. Mauriac, J.E. Pippen, J. Quaresma Albano, S.Z. Gertler, and C.K. Osborne Fulvestrant (Faslodex) versus anastrozole for the second-line treatment of advanced breast cancer in subgroups of postmenopausal women with visceral and non-visceral metastases: combined results from two multicentre trials Eur. J. Cancer 39 2003 1228 1233
127. P. Van de Velde, F. Nique, F. Bouchoux, J. Bremaud, M.C. Hameau, D. Lucas, C. Moratille, S. Viet, D. Philibert, and G. Teutsch RU58668, a new pure anti-oestrogen inducing a regression of human mammary carcinoma implanted in nude mice J. Steroid Biochem. Mol. Biol. 48 1994 187 196
128. P. Van de Velde, F. Nique, J. Bremaud, M.C. Hameau, D. Philibert, and G. Teutsch Exploration of the therapeutic potential of the anti-oestrogen RU58668 in breast cancer treatment Ann. N.Y. Acad. Sci. 761 1995 164 175
129. P. Van de Velde, F. Nique, P. Planchon, G. Prevost, J. Bremaud, M.C. Hameau, V. Magnien, D. Philibert, and G. Teutsch RU58668: further in vitro and in vivo pharmacological data related to its antitumoral activity J. Steroid Biochem. Mol. Biol. 59 1996 449 457
130. J. Devin-Leclerc, X. Meng, F. Delahaye, P. Leclerc, E.E. Baulieu, and M.G. Catelli Interaction and dissociation by ligands of oestrogen receptor and Hsp90: the anti-oestrogen RU58668 induces a protein synthesis-dependent clustering of the receptor in the cytoplasm Mol. Endocrinol. 12 1998 842 854
131. V. Muller, E.V. Jensen, and C. Knabbe Partial antagonism between steroidal and nonsteroidal anti-oestrogens in human breast cancer cell lines Cancer Res. 58 1998 263 267
132. A.E. Wakeling, and J. Bowler Steroidal pure antioestrogens J. Endocrinol. 112 1987 7 10
133. A. Brodie Aromatase inhibitors in breast cancer Trends Endocrinol. Metab. 2002 13
134. A.P. Funke, C. Gunther, R.H. Muller, and R. Lipp In-vitro release and transdermal fluxes of a highly lipophilic drug and of enhancers from matrix TDS J. Control. Release 82 2002 63 70
135. A.P. Funke, R. Schiller, H.W. Motzkus, C. Gunther, R.H. Muller, and R. Lipp Transdermal delivery of highly lipophilic drugs: in vitro fluxes of anti-oestrogens, permeation enhancers, and solvents from liquid formulations Pharm. Res. 19 2002 661 668
136. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U.S.A. 95 1998 4607 4612
137. I. Brigger, P. Chaminade, V. Marsaud, M. Appel, M. Besnard, R. Gurny, M. Renoir, and P. Couvreur Tamoxifen encapsulation within polyethylene glycol-coated nanospheres. A new anti-oestrogen formulation Int. J. Pharm. 214 2001 37 42
138. J.S. Chawla, and M.M. Amiji Biodegradable poly(epsilon-caprolactone) nanoparticles for tumor-targeted delivery of tamoxifen Int. J. Pharm. 249 2002 127 138
139. T. Ameller, V. Marsaud, P. Legrand, R. Gref, G. Barratt, and J.M. Renoir Polyester-poly(ethylene glycol) nanoparticles loaded with the pure anti-oestrogen RU58668: physicochemical and opsonization properties Pharm. Res. 20 2003 1063 1070
140. T. Ameller, V. Marsaud, P. Legrand, R. Gref, and J.M. Renoir In vitro and in vivo biologic evaluation of long-circulating biodegradable drug carriers loaded with the pure anti-oestrogen RU58668 Int. J. Cancer 106 2003 446 454
141. A. Gabizon, and F. Martin Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours Drugs 54 1997 15 21
142. B. Uziely, S. Jeffers, R. Isacson, K. Kutsch, D. Wei-Tsao, Z. Yehoshua, E. Libson, F.M. Muggia, and A. Gabizon Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies J. Clin. Oncol. 13 1995 1777 1785
143. Z. Symon, A. Peyser, D. Tzemach, O. Lyass, E. Sucher, E. Shezen, and A. Gabizon Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes Cancer 86 1999 72 78
144. D.E. Lopes de Menezes, L.M. Pilarski, A.R. Belch, and T.M. Allen Selective targeting of immunoliposomal doxorubicin against human multiple myeloma in vitro and ex vivo Biochim. Biophys. Acta 1466 2000 205 220
145. K.N. Burger, R.W. Staffhorst, H.C. de Vijlder, M.J. Velinova, P.H. Bomans, P.M. Frederik, and B. de Kruijff Nanocapsules: lipid-coated aggregates of cisplatin with high cytotoxicity Nat. Med. 8 2002 81 84
146. D. Papahadjopoulos, T.M. Allen, A. Gabizon, E. Mayhew, K. Matthay, S.K. Huang, K.D. Lee, M.C. Woodle, D.D. Lasic, and C. Redemann Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy Proc. Natl. Acad. Sci. U.S.A. 88 1991 11460 11464
147. T. Cruz, R. Gaspar, A. Donato, and C. Lopes Interaction between polyalkylcyanoacrylate nanoparticles and peritoneal macrophages: MTT metabolism, NBT reduction, and NO production Pharm. Res. 14 1997 73 79
148. C.E. Evans, G.C. Lees, and I.A. Trail Cytotoxicity of cyanoacrylate adhesives to cultured tendon cells J. Hand. Surg. 24 1999 658 661
149. T. Ameller, A. Gougelet, D. Challuau, P. Legrand, V. Marsaud, J.M. Renoir, Long-circulating biodegradable carriers loaded with 4-hydroxy-tamoxifen and RU58668 anti-oestrogens: efficiency to inhibit human breast cancer cell proliferation and tumor progression in xenografts, Submitted for publication.
150. J.S. Carroll, D.K. Lynch, A. Swarbrick, J.M. Renoir, B. Sarcevic, R.J. Daly, E.A. Musgrove, and R.L. Sutherland p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells Cancer Res. 63 2003 4322 4326
151. K. Pettersson, F. Delaunay, and J.A. Gustafsson Oestrogen receptor beta acts as a dominant regulator of oestrogen signaling Oncogene 19 2000 4970 4978
152. G. Lazennec, D. Bresson, A. Lucas, C. Chauveau, and F. Vignon ER beta inhibits proliferation and invasion of breast cancer cells Endocrinology 142 2001 4120 4130
153. J.M. Hall, and D.P. McDonnell The oestrogen receptor beta-isoform (ERβ) of the human oestrogen receptor modulates ERα transcriptional activity and is a key regulator of the cellular response to oestrogens and anti-oestrogens Endocrinology 140 1999 5566 5578
154. R. Lipp Novel drug delivery systems for steroidal hormones Expert Opin. Ther. Patents 11 2001 1291 1299
155. F. Souzé, S. Viardot-Foulcault, S. Somaï, W. Rostène, A. Gompel, P. Forgez, Neurotensin and high affinity neurotensin receptor expression in normal and cancerous human breast tissue, Cancer Res., submitted for publication.
156. S. Dagar, M. Sekosan, B.S. Lee, I. Rubinstein, and H. Onyuksel VIP receptors as molecular targets of breast cancer: implications for targeted imaging and drug delivery J. Control. Release 74 2001 129 134
157. S. Dagar, A. Krishnadas, I. Rubinstein, M.J. Blend, and H. Onyuksel VIP grafted sterically stabilized liposomes for targeted imaging of breast cancer: in vivo studies J. Control. Release 91 2003 123 133
158. C. Reubi, M. Gugger, and B. Waser Co-expressed peptide receptors in breast cancer as a molecular basis for in vivo multireceptor tumour targeting Eur. J. Nucl. Med. Mol. Imaging 29 2002 855 862
159. J.C. Reubi Peptide receptors as molecular targets for cancer diagnosis and therapy Endocr. Rev. 24 2003 389 427
160. D.S. Salomon, N. Normanno, F. Ciardiello, R. Brandt, M. Shoyab, and G.J. Todaro The role of amphiregulin in breast cancer Breast Cancer Res. Treat. 33 1995 103 114
161. R.A. Nunes, and L.N. Harris The HER2 extracellular domain as a prognostic and predictive factor in breast cancer Clin. Breast Cancer 3 2002 125 135
162. N.E. Hynes, and D.F. Stern The biology of erbB-2/neu/HER-2 and its role in cancer Biochim. Biophys. Acta 1198 1994 165 184
163. R.J. Pietras, J. Arboleda, D.M. Reese, N. Wongvipat, M.D. Pegram, L. Ramos, C.M. Gorman, M.G. Parker, M.X. Sliwkowski, and D.J. Slamon HER-2 tyrosine kinase pathway targets oestrogen receptor and promotes hormone-independent growth in human breast cancer cells Oncogene 10 1995 2435 2446
164. W.B. Pratt, and D.O. Toft Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery Exp. Biol. Med. 228 2003 111 133
165. K. Richter, and J. Buchner Hsp90: chaperoning signal transduction J. Cell Physiol. 188 2001 281 290
166. Y.A. Elsayed, and E.A. Sausville Selected novel anti-cancer treatments targeting cell signaling proteins Oncologist 6 2001 517 537
167. P. Sapra, and T.M. Allen Ligand-targeted liposomal anti-cancer drugs Prog. Lipid. Res. 42 2003 439 462
168. M.C. Woodle, G. Storm (Eds.), Long-Circulating Liposomes: Old Drugs New Therapeutics, Landes, Springer-Verlag, Georgetown, TX, 1998, pp. 1-206.
169. T.M. Allen E. Cooper World Markets Research Centre 2000 Pharma. Tech. London 154 160
170. S.T. Pearce, and V.C. Jordan The biological role of oestrogen receptors alpha and beta in cancer Crit. Rev. Oncol. Hematol. 50 2004 3 22